EOLS.US Evolus Inc

Healthcare Pharmaceuticals USA Stocks
6.96 USD
Close of Nov 13, 2026
3.86 9.31
Market cap
USD 461M
P/E
-
P/B
53.71x
ROE
-
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is EOLS.US undervalued?

Graham number

The Graham number of Evolus Inc cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Evolus Inc fundamental analysis

No fundamental analysis for Evolus Inc yet.

Evolus Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Evolus Inc

Evolus, Inc., a performance beauty company, delivers products in the cash-pay aesthetic market in the United States, Canada, Europe, and Australia. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults; and Evolysse, a collection of injectable hyaluronic acid gels, which includes various products, such as mid face, nasolabial folds, lips and e…

Full company profile